Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAX 810-2
- Development stage
- Preclinical
- Lead developer
- NeuroAdjuvants
- Modality
- Peptides
- Administration
- Intravenous, Intperitoneal, Subcutaneous
01
Overview
NAX 810-2 (also known as galanin analogue 810-2) is a systemically bioavailable, peptidomimetic galanin receptor type 2 (GalR2)-preferring agonist developed by the University of Utah and its spinout NeuroAdjuvants. It exhibits a 15-fold greater affinity for GalR2 over GalR1. NAX 810-2 is being investigated preclinically for the treatment of epilepsy, prevention of sudden unexpected death in epilepsy (SUDEP), and management of various pain conditions, including neuropathic and inflammatory pain. By selectively activating GalR2, NAX 810-2 modulates neuronal excitability and provides anticonvulsant and analgesic effects without inducing the GalR1-mediated hyperglycemic side effects typically associated with non-selective galanin agonists.
- Other names
- galanin agonist 810-2galanin analogue 810-2
02
Targets
GALR2 (Galanin receptor 2)
Beyond the preview
Go deeper on NAX 810-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAX 810-2.